source
- Biogen reports mixed results in mid‑stage trial of tau‑targeting Alzheimer’s therapyBiogen disclosed data from a Phase 2 study of its experimental Alzheimer’s drug that targets the tau protein. The trial showed a combination of positive and negative signals, with some measures ind…
- Experts anticipate Daraxonrasib and new GI cancer therapies at ASCO 2026Ahead of the 2026 ASCO Annual Meeting, leading oncologists and researchers focusing on gastrointestinal cancers highlighted the topics they expect to dominate the conference. Central among the buz…